AlgaeHealth Submits NDI for “Industry's First” 24-mg Astaxanthin Dose

November 17, 2016

The New Dietary Ingredient notification for Algae Health Sciences’ AstaZine natural astaxanthin is the first in the industry to exceed a dosage of 12 mg per day, the firm says.

Algae Health Sciences (AlgaeHealth; Irvine, CA), a subsidiary of BGG, announced today it has submitted a new New Dietary Ingredient (NDI) notification to FDA for the industry’s highest astaxanthin dose. The NDI covers AlgaeHealth’s AstaZine natural astaxanthin for daily dosages up to 24 mg/day for a period of 30 days-making it the first astaxanthin NDI dosage to exceed 12 mg/day, according to AlgaeHealth.

“Based on published studies, we generally recommend a dosage of 4–12 mg per day over longer periods; however, we are aware that a growing number of people are voluntarily dosing at well over the 12-mg upper dosage range,” said Lixin Ding, PhD, chief operation officer of AlgaeHealth, in a press announcement. “In particular, many athletes report that they get better results in the 24-mg-per-day dosage range.”

While many of the studies on astaxanthin have found health benefits at dosages between 2 mg and 12 mg, there has been some research that’s found positive effects for dosages above 12 mg/day, including human studies for cardiovascular health benefits, according to AlgaeHealth.

Joe Huff, CEO of AlgaeHealth’s North American operation, explained that there are still other reasons why a 24-mg dosage might be an effective option. For one, new astaxanthin users may benefit from the higher dosage during a “loading phase” for their first 30 days of supplementation to allow the ingredient to concentrate throughout the body. Or, he said, athletes may find it useful to take a higher dosage during the weeks leading up to an important athletic event.

“While we would have preferred not to have the 30-day stipulation, we’re nevertheless happy to have something new to offer in the U.S. market,” Huff said. “We’re always thinking of ways to innovate and wanted to give the market a new option regarding dosage.”

 

Read more:

Astaxanthin Suppliers Are Innovating and Even Exploring New Algae Strains: SupplySide West Report

If FDA’s NDI Guidance Helps Level the Astaxanthin Playing Field, That’s Good, Says AstaReal

AstaReal Warns Against “Misleading” Hype for Algae Life's Astaxanthin Claims

 

Michael Crane
Associate Editor
Nutritional Outlook Magazine
michael.crane@ubm.com